University of California San Francisco
Give to UCSFUCSF researchers aim to radically rethink the role of the microbiome in early life and develop new interventions aimed at preventing childhood diseases.
The gifts will launch new research initiatives on their respective campuses to leverage the growing science of the human microbiome.
Pioneering test called metagenomic next-generation sequencing shown to identify infections better than any standard clinical method.
A two-week course of an experimental immunotherapy called teplizumab dramatically reduced type 1 diabetes (T1D) diagnosis rates in people at high risk for the disease, according to newly published
UC San Francisco cancer biologist Alan Ashworth, PhD, structural biologist Yifan Cheng, PhD, and molecular physiologist Holly Ingraham, PhD, have been elected to the American Academy of Arts and
A delicate operation that involved placing a gene into the brain was found to reduce the severity of motor symptoms in patients with moderately advanced Parkinson’s disease.
UCSF scientists have used the CRISPR-Cas9 gene-editing system to create the first pluripotent stem cells that are functionally “invisible” to the immune system.
UCSF scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies.
Using a mouse model, researchers showed that a drug that temporarily suppresses a key component of the brain’s immune system can prevent radiation-associated cognitive decline.
In new studies conducted at UCSF, a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia.
A new spinal cord injury protocol, based on research by UCSF scientists, is a mixture of revised evaluations and new treatments to personalize care. It has spurred quicker recoveries for patients.
Thanks to a $6.7 million grant, the newly named UCSF-Stanford Pediatric Device Consortium can focus on the development of revolutionary, low-cost gadgets to diagnose and cure pediatric health conditions.
Researchers have identified a new strategy for potentially treating a subset of intractable cancers by decoupling the entire RAS / MAP Kinase signaling pathway from external growth signals.
Students who spent their summer doing laboratory and clinical research alongside BCHO doctors and CHORI scientists are presenting their research at a scientific symposium at CHORI on Friday, August 10.